Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Andrew J. Piper-Valillo"'
Autor:
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Publikováno v:
Clinical Cancer Research. 29:2123-2130
Purpose: The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe1940036ed4218791b9213a90fa6132
https://doi.org/10.1158/1078-0432.ccr-22-3497
https://doi.org/10.1158/1078-0432.ccr-22-3497
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Table S1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented ≤2.5% of the study cohort. Patients with + for “Smo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d11c6eb873c8463a1638764ea648a73
https://doi.org/10.1158/1078-0432.22651605.v1
https://doi.org/10.1158/1078-0432.22651605.v1
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Figure S1. Multi-institution cohort of patients with tumors harboring EGFR Exon 19 deletions. Primary analyses were performed on patients with tumors harboring E746_A750del and L747_A750>P, while investigation into additional uncommon v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0cba566353d18c18e5e83a18181570
https://doi.org/10.1158/1078-0432.22651614
https://doi.org/10.1158/1078-0432.22651614
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6212fa6eedce5e7e3c197a0dc1bfdad4
https://doi.org/10.1158/1078-0432.22651608
https://doi.org/10.1158/1078-0432.22651608
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4455ab4c1799ba13f63c8913712becae
https://doi.org/10.1158/1078-0432.c.6604893.v1
https://doi.org/10.1158/1078-0432.c.6604893.v1
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Figure S2. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with first-line osimertinib. The point estimate for median progression free survival associated with each mutation is listed to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d8399ae66b8472ca2e1786e1b6be97
https://doi.org/10.1158/1078-0432.22651611
https://doi.org/10.1158/1078-0432.22651611